Withers & Rogers gives an insight into the new ways that AI is helping to accelerate drug discovery and highlights the challenges that exist when bringing such innovations to market.
Following on from their recent partnership with Israel Biotech Fund (IBF), EPM caught up with Lonza's Pnina Weitz on the importance of early-stage support for emerging companies, and how robust strategies early on can pave a way to commercialisation.
Terumo Pharmaceutical Solutions (TPS), a manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.
EPM editor and first-time attendee to Pharmapack, Rebekah Jordan, reflects on some of the exhibitors and innovations that stood out at this year’s Pharmapack Paris event 2022.
Noel Maestre, PE, vice president of Life Sciences, and David Estape, technology manager Biotechnology at CRB discuss how virus response rewrote the playbook for vaccine response, but even more change is necessary to deal with emerging threats.
Impel NeuroPharma, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced that it is changing its name to Impel Pharmaceuticals.
Polling conducted across six European countries, with over 6,000 respondents, finds high levels of excitement for gene therapy and medical innovation, particularly for the treatment of rare diseases.
We know disease exists, where it comes from and how it evolves - but we don’t yet know ahead of time when something changes to mark the start of a new disease, a new variant or just an increase in transmission.
Sharon Lamb, partner, and David Gibson, senior associate, McDermott Will & Emery analyse the MHRA consultation to change the UK clinical trial regulations.
